Madison Core Laboratories Welcomes New Chief Financial Officer

HUNTSVILLE, Ala.–(BUSINESS WIRE)–#diagnostics–Madison Core Laboratories, LLC (MCL) announces the appointment of Jerry C. Smith, a seasoned financial executive, as Chief Financial Officer (“CFO”). Smith brings to MCL a CPA background and over 25 years of experience in finance, accounting, revenue cycle management, and mergers and acquisitions in multiple sectors of healthcare and technology. He most … [Read more…]

PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)

IPF study will evaluate efficacy of two doses of LYT-100, one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability and efficacy vs. pirfenidone Bi-monthly, monotherapy dose escalation portion of Phase 1/2 study of LYT-200 for the potential treatment of solid tumors has completed; … [Read more…]

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura’s first VDC product candidate, for the treatment of Non-Muscle Invasive … [Read more…]

IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer

Trial will continue to assess additional primary endpoint of event-free survival WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from a planned interim analysis of the AEGEAN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete response (pCR) compared to neoadjuvant … [Read more…]

Alto Pharmacy Appoints Alicia Boler Davis as CEO to Drive Next Phase of Growth

Alicia Boler Davis brings more than 25 years of experience leading world-class technology operations SAN FRANCISCO–(BUSINESS WIRE)–Alto Pharmacy today announced Alicia Boler Davis will become CEO on September 1, 2022. Alicia was recruited by co-founders and current co-CEOs Jamie Karraker and Matt Gamache-Asselin to scale the business that is transforming a $500 billion industry by … [Read more…]

Spectrum Solutions Wins Two Science & Technology Best of State Awards for Medical Innovation and Laboratory Equipment and Supplies

SALT LAKE CITY–(BUSINESS WIRE)–Spectrum Solutions, LLC today announced it has been awarded two Utah Best of State Science & Technology Awards for Medical Innovation and Laboratory Equipment and Supplies. “We are extremely thankful for these two awards and being recognized with a win, for the second year in a row, under Medical Innovation,” said Bill … [Read more…]

United States Healthcare Distribution Markets, 2019-2021 & 2022-2027: Cumulative Impact of COVID-19 – Focus on California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Healthcare Distribution Market Research Report by Type, End User, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The United States Healthcare Distribution Market size was estimated at USD 223.74 billion in 2021, USD 233.19 billion in 2022, and is projected to grow … [Read more…]

Global Rare Neurological Disease Treatment Market (2022 to 2027) – Growth, Trends, COVID-19 Impact and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rare Neurological Disease Treatment Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering. The rare neurological disease treatment market is expected to register a CAGR of 8.6% during the forecast period. Companies Mentioned US WorldMeds LLC (Solstice Neurosciences LLC) CSL Ltd Merz Pharma GmbH … [Read more…]

LG Chem Renews License Triggering Payment to Avacta

LG Chem will now proceed with Investigational New Drug (IND) enabling studies for Affimer PD-L1 antagonist programme LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that LG Chem Life Sciences … [Read more…]

Ermium Therapeutics Extends Its Initial €6,3 M Funding to €12,3 M to Further Advance Breakthrough Auto-Immune Disease Therapeutics

PARIS–(BUSINESS WIRE)–Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partners. The company is discovering and developing small molecules, orally available, that are aimed at addressing a range of chronic auto-immune … [Read more…]